Introduction
Upwards of 30% of allogeneic hematopoietic progenitor cell (HPC) transplants from related donors and over 50% of transplants from unrelated donors will involve ABO-disparate donor and recipients, 1, 2 and donor and recipient pairs may differ for other RBC antigens, as well. HLA-identical siblings can differ for red cell antigens based on the different genetic locations of the major and minor HLA loci and the genes that control the expression of the over 30 defined groups of RBC antigens (Table 1) . 3 The transplantation of a red cell antigen-disparate HPC product is feasible, if attention is given to the immunohematological considerations necessary in the management of both immediate and delayed hemolytic reactions. Although feasible, the clinical impact of red cell incompatibility on transplant outcomes is uncertain, with various studies showing positive, negative or no effect on important clinical end points such as neutrophil and platelet engraftments, acute and chronic GvHD, disease relapse and OS. Definite short-term adverse consequences of red cellincompatible transplantation are reported, as will be discussed below, but these consequences can be minimized with appropriate graft modifications to remove incompatible red cells and plasma, attention to the pre-transplant conditioning and post-transplant immunosuppressive regimens and prescription of proper blood product support.
The major focus of blood cell-incompatible transplantation has been on the ABO system because of the consequences of acute hemolysis resulting from the infusion of incompatible RBCs or plasma, the delayed hemolytic reactions that may occur as a result of viable 'passenger' lymphocytes infused as a component of the allograft and the delayed RBC recovery resulting from persistent host isoagglutinins directed against donor RBCs (Table 2) . Although there are also frequently disparate non-ABO genes in the population (Table 1) , 4 the primary risk of hemolysis arises from the nearly ubiquitous presence of antibody(s) among both the donor and recipient against ABO antigens that they lack. Thus, it is much more likely that donor/recipient pairs will have clinically significant reactions to ABO antigens than to any other red cell antigen group. However, non-ABO antigen systems have been implicated in post-transplant reactions and red cell incompatibility encompasses ABO, rhesus (Rh) and other red cell antigen systems. 5, 6 Definition of RBC-incompatible transplants Red cell incompatibility may be classified into two major categories, one in which the recipient has antibodies directed against donor red cells with the potential of acute hemolytic transfusion reaction upon infusion of the stem cell product and delayed recovery of red cell function after transplantation (major incompatibility), and one in which the donor has antibodies against the recipient (minor incompatibility). Although the latter may rarely cause difficulty from infusion of incompatible plasma with high isoagglutinin titers, B-lymphocytes carried in the component ('passenger lymphocytes') can produce isoagglutinins resulting in a delayed transfusion reaction usually 7-12 days after transplantation. Bi-directional incompatibility (for example, group A donor with a group B recipient) raises the risk of both consequences.
Clinical outcomes of RBC-incompatible transplants
Numerous reports of the effect (or lack thereof) of transplantation using HPC from ABO-disparate donors have been published (Tables 3a and b) , including large registry studies; 2, [7] [8] [9] studies limited to PBPCs, [10] [11] [12] BM 1, 2, 7, 9, [13] [14] [15] [16] [17] [18] [19] [20] or cord blood sources of HPC; 21 reducedintensity conditioning regimens; 8, 10, 11, 22, 23 T-cell-depleted grafts; 17, 19 and cohort studies from single or limited number of institutions. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Four large registry studies of HPC recipients including two studies of unrelated donor transplantation showed inconsistent results with some deleterious effect on engraftment, GvHD or survival being observed in some patient groups but not in others (Table 3a) . Registry data studies strictly limited to PBPC Shown are the chromosome locations of the major HLA and various RBC antigens for which post transplant hemolytic reactions have been reported. Shown also are the incidence of the relevant antigen for three different ethnic groups.
Table 2
Immunohematological consequences of ABO-incompatible transplantation or cord blood transplantation have not yet been reported. Most published studies involve retrospective analyses of data from single institutions with limited number of patients. No consistent effects for a variety of outcomes can be discerned from these reports, possibly a reflection of the varying number of patients studied; differing diagnoses; differing donor and HPC product selection criteria; and use of various cell processing, transfusion support and conditioning and GvHD prophylaxis regimens (Table 3b) . Moreover, statistical analyses vary with some reports combining patient groups precluding the ability to discern consistent effects from either minor or major incompatible transplants. Donor considerations have usually been ignored, such as the effect of previous exposure of donors to blood cell antigens, 34 although the deleterious effects of exposure to antigens reflected by donor parity are well recognized. 9, 35 Even dietary changes such as the ingestion of probiotics can affect the isoagglutinin titers in a patient or donor. 36 It must also be recognized in reviewing the published reports of red cell-incompatible transplants that donors and recipients are classified by the phenotype of the RBCs. Patient/donor pairs may have differing genotypes from allelic variations of isoantigens that could serve as minor histocompatibility antigens (mHLAs), leading to increased risks of graft failure or of acute or chronic GvHD that would not be detected in the more broadly defined population. 37, 38 The red cell membrane contains numerous proteins of wide structural diversity, including carbohydrate epitopes on glycoproteins and/or glycolipids, and peptide antigens that serve as membrane transporters, adhesion molecules and receptors, enzymes and structural proteins. 39, 40 Polymorphisms among these antigens may lead to the production of clinically significant antibodies in recipients after exposure to blood-containing products.
Do blood cells present minor HLA antigens?
Given the diversity of RBC antigens and their associated polymorphisms, and the likely inability to match donors and recipients for all red cell antigen polymorphisms, most patients outside syngeneic transplantation are likely recipients of HPC grafts that could give rise to red cells with disparate antigens. Recognized early in the development of transplantation science was the enhanced host-vs-graft reaction as a consequence of blood transfusions given before transplantation, leading to a higher risk of engraftment failure for patients undergoing treatment in the management of aplastic anemia. 41, 42 This enhanced host-vsgraft reaction, which was observed in recipients of HLAcompatible HPC and explored in canine models of transplantation, 43 likely is the result of immunization from mHLAs expressed on blood cells. In mouse models, pretransplant exposure to red cells or platelets can induce rejection of transplanted HLA-compatible BM cells as a result of alloimmunization against mHLAs. 44 , 45 Bean et al. 46, 47 reported that irradiation of blood products could prevent immunization to minor dog leukocyte antigens (minor canine histocompatibility antigen) with reduced risk of graft rejection in canine models of dog leukocyte antigen-compatible related and unrelated donor transplants. However, similar studies of the effect of incompatibility for platelet alloantigens in human HPC transplantation have not yielded similar observations. 48 It is reasonable to assume that current transplant conditioning and post-transplant immunosuppressive regimens obscure the effects of immunization to blood cell mHLAs and that changes in these regimens could allow mHLAs to emerge as a factor affecting transplant outcomes.
Does ABO incompatibility affect neutrophil and platelet engraftments?
The presence of host-anti-donor isoagglutinins can delay RBC recovery and increase post-transplant red cell transfusion requirements. 1, 2, 7, 10, 11, 13, 18, 21, 22, 25, 27, 28 No clear effects of ABO incompatibility have been found for neutrophil or platelet engraftments even though cells of these lineages express ABO antigens or can adsorb antigen from the plasma of secretors. 49 Two of the four registry studies correlated major ABO incompatibility with a median one or two day slower neutrophil engraftment after BMT, 2, 8 but a third equally large study involving unrelated donors did not find a difference. 9 One cohort study found slower neutrophil engraftment for ABOincompatible compared to ABO-compatible graft recipients, but this analysis pooled all ABO-incompatible recipients and the specific effects of major or minor incompatible transplantation were not analyzed. 32 Seebach et al. 7 proposed a direct effect of recipient isoagglutinins, possibly by adsorption onto the cell surface, on donor granulopoiesis to explain the delayed recovery of neutrophils after major ABO-incompatible transplantation, although loss of hematopoietic progenitor cells (HPC) during processing of major ABO-incompatible grafts to remove incompatible RBCs may also be an explanation for this observed delay in neutrophil engraftment. 2 A delay in platelet recovery was reported in one of the registry studies for recipients of major ABO-incompatible BM grafts. 2 Two cohort studies involving related donor PBPC transplants or cord blood transplants reported similar findings, 10, 21 as did a meta-analysis of seven cohort groups (but only for recipients of unrelated vs related donors). 33 Platelets express ABO antigens, 49 and increased platelet transfusion requirements for recipients of major ABO-incompatible grafts have been reported. 10, 21 It is conceivable that the lower platelet transfusion requirements after transplantation using non-myeloablative conditioning allowed the detection of an effect of residual host isoagglutinins on thrombopoiesis reported in one cohort study, 10 which would otherwise be obscured by the higher transfusion requirements after transplantation using a traditional conditioning regimen, but an increased platelet transfusion requirement has not been observed in other studies. 11, 22, 50 In one study using non-myeloablative conditioning, recipients of minor ABO-incompatible transplants required a greater number of platelet transfusions. 11 Remberger et al. 51 reported a 14.9-fold higher risk of engraftment failure for recipients of major ABO-incompatible unrelated donor BM or PBPC. Graft failure was observed in 6 of 224 patients studied, including 4 of 67 major ABO-incompatible and 2 of 16 bi-directional incompatible transplants. Three of the six received cells from donors mismatched at one or more HLA class one antigens and HLA mismatch was also a significant predictor of graft failure in the multivariate analysis. Three of the six experienced primary graft failure and secondary graft failures were seen in the other three. Kimura et al. 2 also found, in univariate analysis, an increased risk of secondary graft failure for recipients of major, minor and bi-directional ABO-incompatible unrelated donor BMTs, but this factor became insignificant in multivariate analysis controlling for other variables. In a small study of 27 patients undergoing reduced-intensity conditioning with PBPC transplantation, Badros et al. 52 reported mixed chimerism at day 30 for three of six patients receiving major ABO-incompatible grafts compared with 2 of 18 receiving compatible grafts (P ¼ 0.01). One of the incompatible graft recipients experienced engraftment failure. The small number of patients in the reports of engraftment failure raises the question as to the biological relevance of the statistically significant correlation. None of the other analyses of engraftment after ABO-incompatible transplantation have found a higher risk of this complication and ABO incompatibility cannot, at this time, be cited as a cause of primary or secondary graft failure. 2, [11] [12] [13] [14] [15] 22, 23 Does ABO incompatibility change the risks of GvHD?
Presumably, the expression of blood cell antigens on the endothelial and epithelial tissues in the body could be a target for the GvH response, resulting in a higher incidence of GvHD and risk of transplant-related complications for recipients of red cell-incompatible grafts, although such an effect has not been consistently demonstrated. 53 Bacigalupo et al. 16 proposed a potential increased risk of acute GvHD for recipients of minor ABO-incompatible transplants compared with that faced by recipients of ABO-compatible grafts, and a decreased risk for recipients of major ABOincompatible transplants. This hypothesis is based on an expected recognition by donor lymphocytes carried in the graft of ABO antigens expressed on non-hematopoietic tissues of the host leading to the initiation or increasing the ultimate severity of acute GvHD (aGvHD). These authors reported the development of aGvHD in 82% of recipients of minor ABO-incompatible BM grafts compared with 54% of recipients of ABO matched and 39% of recipients of major-incompatible grafts (P ¼ 0.006), supporting this hypothesis. Rh incompatibility was not predictive. KeeverTaylor et al. 17 also observed a higher risk of moderate to severe (grades II-IV) aGvHD for minor ABO-incompatible recipients of T-cell-depleted grafts that should not have contained 'passenger lymphocytes'.
Others have found a correlation with minor ABOincompatible transplants only for severe (grades III and IV) aGvHD 2, 28 or, in one study, only with clinically insignificant (grade I) aGvHD. 20 A decreased risk of aGvHD for recipients of major ABO-incompatible grafts was not observed in the other cohort studies (Table 3b) . Resnick et al. 23 found a statistically nonsignificant trend to a higher risk of aGvHD for recipients of ABO-incompatible compared to ABO-compatible grafts, but specifically noted a higher proportion of deaths attributed to acute or chronic GvHD for patients receiving ABO-incompatible grafts. Analyses of registry data are conflicting, with Seebach et al. 7 reporting severe (grades III/IV) aGvHD limited to recipients of bi-directional incompatible grafts, and Kimura et al. 2 reporting severe (grades III/IV) aGvHD of the liver only for recipients of major or minor ABO-, but not bi-directional incompatible grafts (Table 3a) .
None of these reports of ABO-incompatible transplants described a change (increased or decreased) in the risk of developing chronic GvHD (Tables 3a and b) .
Does ABO incompatibility affect the risk of disease relapse?
Most studies demonstrated no effect on this outcome of transplantation, either an increase or a decrease in the risk (Tables 3a and b) 11,20,22,27 including studies of patient cohorts receiving truly non-myeloablative conditioning in which any graft-vs-tumor effect may be more evident.
11,22
Erker et al. 26 reported a significantly increased risk of relapse for recipients of minor or bi-directional incompatible grafts compared with ABO-compatible and major incompatible grafts, but did not specifically report a comparison of these groups to patients receiving ABOcompatible grafts. They attributed this observation to the small number of patients studied, and possibly not of biological relevance. Mehta et al. 20 reported in univariate analysis (P ¼ 0.028) a decreased risk of relapse for recipients of ABO-mismatched grafts compared with recipients of ABO-matched transplants. This factor became nonsignificant in multivariate analysis (P ¼ 0.086), although in contrast to the report by Erker et al., 26 recipients of minor and bi-directional incompatible grafts had the lowest risk of relapse, which translated into improved OS. Similarly, Worel et al.
11 reported a nonsignificant (P ¼ 0.056) trend to lower relapse in recipients of ABO-incompatible compared to ABO-compatible grafts, as did Blin et al. 27 The effect may be more obvious in patients being treated for acute leukemia.
Does ABO incompatibility affect non-relapse mortality?
The infusion of ABO-incompatible grafts may result in severe immediate or delayed transfusion reactions, and numerous patient deaths have been attributed to the immunohematopoietic consequences of ABO-incompatible transplantation. Despite this increased risk, a consistent effect of ABO-incompatible transplantation on non-relapse mortality, however, has not been found (Tables 3a and b) . The use of dose-intense conditioning regimens could obscure detection of such an effect and three of the four reports that limited analysis to patients receiving reducedintensity conditioning found increased mortality for recipients of ABO-incompatible grafts. 8, 11, 22 Worel et al.
11
reported an increased risk of non-relapse mortality in a group of patients conditioned for transplantation with a Shown are analyses of outcomes of ABO-incompatible transplants from registry databases. *P-value is given where a significant correlation with outcome was found. 22 using the same regimen but with much larger patient cohorts, did not detect an increase in non-relapse mortality. An increased risk of nonrelapse mortality was reported by the Japanese Marrow Donor Program for recipients of major or minor incompatible grafts in a study that included both standard and reduced-intensity conditioning regimens. 2 Similar results were not found for analyses from other registries. 9, 13 Does ABO incompatibility affect survival?
Any effect of ABO-incompatible transplantation on OS is, likewise, inconsistently detected, but reflects the experience with non-relapse mortality. The Japanese Marrow Donor Program found a decreased survival for recipients of major, but not minor or bi-directional incompatible grafts, 2 and the French registry reported lower survival for recipients of minor, but not major incompatible grafts. 8 A deleterious effect has been more consistently (although in only a few of the cohort studies) reported for recipients of minor or bidirectional incompatible grafts, 14, 26, 28 or in analysis limited to subgroups of patients. 18 A specific attribution of patient death to the immunohematological consequences of ABOincompatible transplantation has not been published.
Does Incompatibility for Non-ABO Red Cell Antigens Affect Transplantation?
Non-ABO red cell antigens are much less likely to present an increased risk of immediate or delayed hemolysis because of the lack of naturally formed antibodies found in the ABO system. Healthy donors are very unlikely to have been exposed to red cell antigens through blood transfusions. However, like minor ABO-incompatible transplantation, donor lymphocytes of a different phenotype may produce alloantibodies on engraftment resulting in hemolysis, possibly severe, of red cells in the recipient, which would be worsened by the transfusion of incompatible red cells during the initial post transplant period. The development of non-ABO red cell antibodies after transplantation is an uncommon event, occurring in about 2-9% of patients.
6,54-58 de la Rubia et al. 56 studied 217 allograft recipients and identified eight recipients (3.7%) who developed non-ABO alloantibodies after HSC transplantation at a median of 23 days after transplantation (range, 16-672 days). The type of conditioning regimen, GvHD prophylaxis or source of cells did not predict for this event, but development of alloantibodies occurred for 2 of 156 (2.1%) patients receiving ABO-compatible grafts and for 5 of 62 (9.6%) of patients receiving ABO-incompatible grafts, suggesting an enhanced immunological effect in the ABO-incompatible setting. Four of six patients for whom antibody specificity was identified developed antibodies directed against antigens absent in both the donor and recipient, indicating that alloantibodies can be developed by host or donor lymphocytes against red cell Shown are analyses of outcomes of ABO-incompatible transplants from cohort studies. *The P-value is given where a significant correlation with outcome was found.
antigens transfused during the peri-transplant period despite the profound immunosuppression of the transplant recipient. Abou-Elella et al. 55 studied 192 patients, of whom 148 received autologous transplantation. Seven patients had alloantibodies before transplantation and an additional four (2.1%) developed new alloantibodies. In this same population, 8 of 180 patients developed anti-HLA antibodies.
Despite the potential development of alloantibodies after transplantation, few patients experience clinically relevant adverse effects, with individual case reports of hemolysis being published. 57, 59 Erker et al. 26 studied the effects of differences in ABO, Rh and Kell systems on transplant outcomes for 143 patients. Fifteen patients had major Rhincompatible donors and 17 minor Rh-incompatible donors. An increased red cell transfusion requirement was found for recipients of Rh-incompatible grafts in the second month after transplantation, but there was no effect on the total quantity of red cells transfused through the transplant course. Patients who received Rh-incompatible grafts (either major or minor) had a significantly decreased probability of OS, but no effect was found on neutrophil engraftment, acute or chronic GvHD or relapse. Kell mismatching had no effect on any of the studied transplant outcomes in this limited group of patients. In contrast, a larger study of 258 patients including 18 major and 27 minor Rh-mismatched donors found no effect of Rh incompatibility on OS, TRM or acute or chronic GvHD. 60 
Does cell source affect outcomes of ABO-incompatible transplants?
The available sources of HPC differ with regard to the volume of RBCs and plasma contained, but also the number and maturity of lymphocyte populations. 61 BM and cord blood products mirror the peripheral blood of the donor, with only modest dilution of RBCs and plasma from salt solutions and anti-coagulants added during the collection procedures. Accordingly, a 1000 mL BM product will usually contain about 350-450 mL of RBCs. 62 Similarly, cord blood units typically of about 100 mL total volume may contain proportionately large volumes of RBCs, although pre-storage processing is frequently performed to reduce the overall volume and red cell content. 63 PBPCs collected by apheresis techniques are characterized by low volumes of RBCs, but approximately a 10-fold greater number of lymphocytes including Blymphocytes that may increase the risk of delayed hemolytic transfusion reactions (and aGvHD). 61, 64 Unique to cord blood transplantation is the lack of immunization of lymphocytes to red cell antigens reducing the risk of delayed hemolytic transfusion reactions from passenger lymphocytes. 65 The immunohematological consequences of major ABO-incompatible transplants using cord blood cells were similar to that seen with other sources of HPC, including greater RBC transfusion requirements. Pure RBC aplasia was not observed, but the number of patients was small. No comparative studies for these cell sources have been published describing the effects of ABO incompatibility on transplant outcomes. It is important that the RBC and plasma contents of these various graft sources be considered in the management of the individual patient.
Management of red cell-incompatible transplants
Major ABO-incompatible transplantation The immediate complication of major ABO-incompatible transplantation is the necessity of infusing incompatible RBCs into the recipient with the potential for serious and life-threatening immediate hemolytic reaction. Although the volume of incompatible cells infused predicts the likelihood of symptomatic reaction, 66 unfortunately there is no 'safe' quantity of red cells below which hemolytic transfusion reactions will not occur. In a review of ABOincompatible RBC transfusions that classified patients into receiving more or less than 50 mL of incompatible RBCs, 16 of 36 patients receiving the larger volume experienced signs or symptoms of a hemolytic reaction, 10 experienced acute renal failure and 6 patients died. 66 For the 12 patients receiving the smaller volume of incompatible cells, no deaths were attributed to the inappropriate transfusion, only three patients experienced signs or symptoms of hemolysis, and no patient developed renal failure. The relationship of isoagglutinin titers of the transfusion recipient to the likelihood or severity of adverse sequelae of incompatible red cell infusions was not described. Accordingly, allograft recipients can experience serious hemolytic reactions to even the small volume of RBCs, typically less than 10 mL, 67 contained in a PBPC or a BM product depleted of red cells using apheresis technology. 66, 68, 69 The risk of acute hemolytic reactions can be decreased by either reducing the red cell content of the graft or the isoagglutinin titers of the recipient. Apheresis devices and hydroxyethylstarch or dextran sedimentation are commonly used to remove red cells from marrow components for major ABO incompatibility. 62, 69, 70, 71 Braine et al. 69 were able to reduce the red cell contents of BM grafts from a mean of 354±115 to 21.0±9.5 mL by processing with a Haemonetics (Braintree, MA, USA) apheresis device with manual collection of buffy-coat cells. Nine of 15 patients transplanted experienced symptoms of a hemolytic transfusion reaction including fever, chills and hypertension, although the reactions may have been ameliorated by preinfusion medication with diphenhydramine, hydrocortisone and mannitol. Larghero et al., 62 using the continuous flow Cobe Spectra (CaridianBCT, Lakewood, CO, USA) device, were able to reduce the red cell content of BM grafts from 309.9 to 4 mL while retaining 82.2% of CD34 þ cells, and noted infusion-related symptoms that were not related to the volume of red cells infused or recipient isoagglutinin titers. Secondary processing of a PBPC component already containing low quantities of RBCs is not likely to be effective in further reducing the quantity of RBCs or risks of infusion reactions, and will likely result in HPC loss.
Loss of HSCs is the major risk of red cell depletion of the graft and one management approach is to require red cell depletion only if the recipient has a high anti-donor isoagglutinin titer (Figure 1) . 15 Alternately, the risk of acute hemolytic reactions may be lessened by reduction of recipient isoagglutinin titers by plasma exchange or immunoadsorption, 15, 72 by infusion of donor-type RBCs, 68 or combinations of both. 73 The reduction of recipient isoagglutinins by plasmapheresis or immunadsorption allows ABO-incompatible kidney (and other solid organ) transplantation, and has been used in conjunction with splenectomy or rituximab infusions to prevent post transplant rebound of isoagglutinin titers. 74, 75 Multiple procedures are usually necessary and isoagglutinins may rebound rapidly after treatment requiring post-transplant plasmapheresis, as well. Critical isoagglutinin titers for survival of the kidney graft, 75 or for avoidance of reactions during HPC infusion (Figure 1 ), remain undefined. Plasmapheresis is associated with frequent minor toxicities and increases the cost of transplantation. 74 Rebound of isoagglutinins after HPC transplantation, while described, does not appear to cause significant toxicity. 15, 76 Pure red cell aplasia and resolution of anti-donor antibodies The presence of recipient isoagglutinins directed against donor RBC antigens results in delayed recovery of red cell function (pure red cell aplasia, PRCA) that may persist for months or years after transplantation, resulting in increased transfusion requirements and transfusion-related hemosiderosis. In the vast majority of patients undergoing major incompatible transplantation, there is rapid clearance of anti-donor isoagglutinins resulting in a slight increase in RBC transfusion requirements compared with recipients of ABO-compatible transplants. 76 The gradual disappearance of host anti-donor isoagglutinins after major ABO transplantation is likely a reflection of graft-vs-host reactivity depleting host mature B-lymphocytes and plasma cells. In a review of 383 patients undergoing related (n ¼ 155) or unrelated (n ¼ 228) major ABO-or bi-directional incompatible transplants, Mielcarek et al. 1 27 found faster disappearance of anti-donor IgM hemagglutinins in unrelated recipients of BM (median time, 36 vs 44 days, P ¼ 0.03) and patients with severe aGvHD (35 vs 59 days, P ¼ 0.001), but did not find this difference for recipients of PBPC. Titers may persist longer for patients treated with non-myeloablative conditioning regimens that would be less immunosuppressive. 78 For example, Wang et al. 22 found only pretransplant titers predicted for the rate of fall for patients conditioned with a non-myeloablative regimen based on single-fraction TBI.
A small proportion of patients will experience a much slower decay of anti-donor isoagglutinin titers, resulting in normal myelopoiesis and thrombopoiesis, but ineffective erythropoiesis. BM samples may show normal early erythroid precursors despite ongoing transfusion requirements. This observation is explained by the development of blood group antigens at different points in erythropoiesis. In vitro studies, for example, demonstrated the expression of ABO and Kell antigens during the EPO-independent phase of colony growth, with other antigens such as Rh developing during the later EPO-dependent phase and Jk and Lu antigens appearing last. 79, 80 The primary consequence of delayed red cell recovery is the need for continued red cell transfusions and the development of transfusional hemachromatosis. The risk appears to be higher in recipients of older age, a donor of blood group A, and use of certain (but not all) non-myeloablative conditioning regimens. 78, [81] [82] [83] [84] [85] The incidence of PRCA is likely influenced by the degree of suppression of recipient B cells achieved by various factors including the intensity of the conditioning regimen, posttransplant immunomodulations such as rapid withdrawal of immunosuppressive medications and the occurrence of GvHD. Stussi et al. 73 proposed pre-transplant plasmapheresis and post-transplant infusion of donor type RBCs to decrease the risk of developing PRCA by reducing the titer of anti-donor isoagglutinins after transplantation. Plasmapheresis is not a completely effective preventive strategy; it is possible for host anti-donor isoagglutinin titers to increase after transplantation. 15, 86 Treatment of PRCA Any case reports describing the effective treatment of PRCA must be interpreted with caution in that anti-donor isoagglutinins will fall spontaneously over time. EPO has been reported to be effective in limited case reports in the treatment of patients with post-transplant red cell aplasia. [87] [88] [89] The mechanism of response is not clear in that PRCA appears to be a result of destruction of red cell precursors as isoantigens become expressed and not a lack of production. Others found no effect of EPO on the transfusion requirements of patients with PRCA. 78, 81, 90 The patients reported to have responded to erythropoietic agents appear to have generally had lower isoagglutinin titers than patients who did not respond, although a critical titer under which erythropoietic stimulation is likely to be effective is not defined.
Plasma exchange will transiently decrease the titer of isoagglutinins in the peripheral blood. However, plasma exchange will not affect the ongoing production of isoagglutinins and high-affinity antigens can result in hemolysis even at low titers. Case reports of successful plasmapheresis are published. 81, 90 Rituximab is a monoclonal anti-CD20 monoclonal antibody that targets mature B-lymphocytes, but not precursor B cells or mature plasma cells. Effective in the treatment of malignant disease such as B-cell lymphoma, rituximab is being explored in the treatment of autoimmune diseases including autoimmune hemolytic anemia. Case reports describing the treatment of patients with red cell aplasia after major ABO-incompatible transplantation have been reported. 27, 81, 91, 92 Although this response is likely a result of depletion of B cells producing isoagglutinins, the mechanism of action and the overall efficacy of this treatment approach cannot be determined from these limited reports.
Polyclonal anti-thymocyte globulins can induce apoptosis of naı¨ve and memory B cells and terminally differentiated plasma cells. 93 Case reports of the successful use of both anti-lymphocyte globulin and anti-thymocyte globulin have been published. [94] [95] [96] The pre-transplant administration of anti-thymocyte globulin is reported to reduce the risks of GvHD and to improve survival, but reports in the management of ABO-incompatible transplants have not been published.
The more rapid clearance of host anti-donor isoagglutinins observed for recipients of unrelated donor cells and patients developing acute GvHD suggest that mechanisms to enhance the graft-vs-host response may be effective in the management of patients with red cell aplasia. Verholen et al. 97 and Ebihara et al. 98 described the successful treatment with repetitive doses of donor lymphocytes of two patients who failed previous treatments with changes in immunosuppressive treatment, high-dose EPO, plasma exchange and rituximab therapy. Lymphocyte infusions may result in the development of GvHD that may be more difficult to manage and of higher risk to the patient than continued transfusion support until eventual resolution of anti-donor isoagglutinins.
Minor ABO-incompatible transplantation
The primary risk of minor ABO incompatibility is delayed red cell hemolysis resulting from the infusion of immunocompetent lymphocytes and plasma cells. Passive hemolysis from infusion of anti-recipient isoagglutinins in the HPC product is an unlikely event, except for use of donors with high isoagglutinin titers or for recipients of small blood volume. Delayed hemolytic reactions may be fatal if appropriate blood transfusion support (avoiding the infusion of donor-type red cells) is not initiated before the transplant (see section on transfusion support). Delayed hemolytic transfusion reactions typically occur with infusion of incompatible RBCs into a previously exposed patient, in whom the titer of the ensuing serum antibody against the incompatible antigen has fallen below detectable levels, 99 resulting in the production of an amnestic response 7-10 days later, with a subsequent rise of antibody titer and brisk hemolysis. In the setting of minor ABOincompatible transplantation, it is the infused donor Blymphocytes ('passenger lymphocytes') reactive to host red cell antigens that are responsible for the production of antihost isoagglutinins and hemolysis of host RBCs. The usual time course to the first appearance of rising titers and hemolysis is about 7-10 days after transplantation (Tables  4a and b) , and the hemolysis is usually abrupt in onset, indicating that this is not a result of passive transfer of isoagglutinins in the plasma of the HPC product. One report describes no evidence of delayed anti-host isoagglutinins after cord blood transplantation, 65 which would be expected in that isoagglutinins develop after birth as a result of exposure to sources of antigens other than RBCs. 100 Several case reports of severe red cell hemolysis, including fatal cases, after minor ABO-incompatible HPC transplantation have been reported (Tables 4a and b) . [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] Red cell transfusion requirements during the period of active hemolysis may exceed the calculated blood volume of the recipient, 104, 109, 118 probably a result of passive adsorption of antigen from destroyed red cell onto the surface of transfused group O cells, allowing immunological destruction of these transfused cells, as well. The majority of patients reported were of ABO group A with a donor of group O, suggesting that the recipient of group A is at higher risk of this complication of transplantation. The majority of reported cases also involved use of CYA alone for post transplant immunosuppression leading to the recommendation that agents effective in preventing B-cell proliferation would be protective. The choice of conditioning regimen should not have an effect on the incidence or severity of delayed hemolytic reactions, except that conditioning regimens are often linked to particular posttransplant immunosuppression regimens. Worel et al. 119 described 4 of 25 patients experiencing hemolysis after PBPC transplantation, and noted that three of the patients received non-myeloablative conditioning regimens. However, these three patients were in a group of 10 who received post-grafting immunosuppression with CYA and mycophenolate mofetil, and the fourth patient was one of two who received CYA alone after myeloablative conditioning. None of the 13 patients who received a myeloablative conditioning regimen followed by post-grafting immunosuppression with an MTX-containing regimen experienced hemolysis.
It has been suggested that use of a reduced-intensity conditioning regimen and PBPC with its larger quantities . 6, 34, 54, 58, 102 Leo et al. 6 described severe hemolysis occurring 17 days after ABO/Rh-compatible transplantation for a Jk(aÀb þ ) recipient receiving cells from a Jk(a þ b þ ) donor. Testing confirmed the presence of alloantibody of anti-Jk a specificity at a titer of 1:8. Young et al. 59 described two patients who developed alloantibodies of anti-Jk a specificity after transplantation.
Management of minor ABO-incompatible transplants
It is important that patients do not receive red cell transfusions of host type after transplantation with minor ABO-incompatible grafts. It must be understood that the appropriate red cell type to be transfused cannot be determined by blood bank testing techniques-ABO typing will only identify host red cell type, not that of the donor, early after transplantation. Therefore, the blood bank must be notified of the ABO-incompatible transplant in order that appropriate blood component support can be arranged. Transplant programs performing allogeneic transplantation must, as part of their quality program, have in place an error-proof mechanism for such notification. Pre-transplant red cell exchange should reduce the risk of severe hemolysis by reducing the quantity of target cells. Worel et al. 121 described a lower incidence of delayed hemolysis at their one center after introducing a policy of pre-transplant red cell exchange. Only 1 of 20 patients treated in this manner showed minor evidence of hemolysis. Interestingly, the authors also reported lower TRM (16 vs 53%, Po0.05) and an improved survival at 1 year after transplantation (65 vs 40%, Po0.05) compared with a historical control group not treated with red cell exchange. Gajewski et al. 118 similarly described less brisk period of hemolysis with lower red cell transfusion requirements for patients who underwent pre-transplant red cell exchange.
Post-transplant immunosuppressive regimens containing an anti-B-cell proliferative agent appear important in preventing delayed hemolytic reactions, and the risk of developing a robust anti-host response appears to be much reduced by administration of regimens that include MTX. 118 However, awareness of possibility of a delayed transfusion reaction is important for proper management of hemolysis that may be brisk and life-threatening. Clinicians must be vigilant to recognize the onset of hemolysis and immediately implement therapy to maintain an appropriate hemoglobin level and avoid renal failure. Management of hemolysis is usually supportive care and transfusion of group O red cells or red cells compatible with the donor. Rituximab has been given to one patient with severe hemolysis. 111 Passive hemolysis directly resulting from the infusion of HPC products from donors with high anti-host isoagglutinin titers may occur if large volumes of plasma are infused into the recipient. Clinically significant hemolysis is a rare, but potentially severe complication of administering an ABO-mismatched platelet transfusion, particularly for single donor platelet products containing a large volume of plasma collected from high-titer group O donors. 122 Unfortunately, a safe titer for platelet donors under which passive hemolysis will not occur has not been defined and various technologies are used in measuring isoagglutinin titers, further complicating analysis of risk. 122 In their review of passive hemolysis after platelet transfusion, Josephson et al. 122 collated case reports for 11 pediatric and 20 adults, all but two of whom were A or AB recipients of group O platelets with a wide range of isoagglutinin titers. In a separate report, that group proposed defining high titers as being equal or greater than 1:64 for IgM isoagglutinins and 1:256 for IgG isoagglutinins. 123 Additional risk factors for passive hemolysis include a larger total volume of the platelet product infused, a smaller blood volume of the recipient and group O donor with a group A or AB recipient. 124 In addition to giving attention to post-transplant immunosuppression regimens, an appropriate management strategy for transplantation of minor ABO-incompatible HSC products is to reduce the volume of plasma in the products being infused to avoid the risk of passive hemolysis, particularly for donors with high antihost red cell isoagglutinin titers, and pediatric patients with small blood volumes. Particular attention should be given to recipients of blood group A or AB receiving HPC products from a group O donor. Each transplant center should define limits of donor isoagglutinin titer/plasma volume permissible in a minor ABO-incompatible HPC product (Figure 1 ).
Transfusion support for red cell-incompatible transplantation
Transfusion support of the red cell-incompatible HSC recipient must consider both the immunohematology of the recipient and the donor. 125 The reports of hemolysis involving non-ABO red cell antigens emphasize the importance of screening both donor and recipient for the presence of other antibodies and providing appropriate blood component support before and after transplantation. Further investigation of positive antibody screens for either the donor or recipient should be performed to determine donor-patient red cell compatibility before transplantation, and patient records reviewed for a history of red cell antibodies. Routine donor-recipient serological crossmatch testing for most healthy donors is unlikely to improve patient safety, [126] [127] [128] but each transplant program should establish policies regarding the appropriate testing of the donor-recipient pair. The transplant program requesting blood components must have a mechanism alerting the transfusion service of the need to use components that would not be first choice in the nontransplant setting, but that may be critical for the patient undergoing HPC transplantation.
The recipient should not receive incompatible red cells before or after transplantation, except as part of an intentional management strategy (for example, major ABO incompatibility); for red cell-incompatible transplants, red cell compatibility with both the recipient and the donor must be accommodated to avoid both immediate and delayed hemolytic reactions. In general, red cell (or granulocyte) support of the major incompatible recipient should be of recipient type and of the donor type for minor incompatible recipients (Table 5) . For most patients, this translates into using group O red cells. Plasma product support (platelets, fresh-frozen plasma) is the opposite, with donor type being used for major incompatible recipients and recipient type for minor incompatible recipients. The infusion of RhD-incompatible blood products will induce the development of RhD antibodies in a small proportion of patients, possibly with an increased risk after non-myeloablative conditioning. [129] [130] [131] Although the incidence of antibody development is low, leading some authors to suggest that use of RhD-incompatible blood components is acceptable after transplantation, clinically relevant hemolysis has been reported. The administration of appropriate doses of Rh immunoglobulin (20 mg of Rh immunoglobulin per 1 mL of RBCs given within 72 h of exposure is suggested) can prevent immunization of Rhnegative patients exposed to Rh-positive products. 132 One group described favorable results of transfusing only ABO-identical red cells and platelet products for patients undergoing autologous or allogeneic transplantation, claiming improved survivals compared with results published by other transplant programs. 133 A retrospective study of pediatric patients found a correlation between ABO-incompatible plasma infusions and hepatic sinusoidal syndrome, possibly a consequence of expression of ABO antigens in the liver. 134 Multivariate analysis found only two factors that predicted for this event, use of melphalan in the pre-transplant conditioning (P ¼ 0.006) and transfusion of platelet concentrates containing ABO-incompatible plasma (P ¼ 0.003).
Transplant program standards
Possible RBC disparities and the management of these must be part of the evaluation of donors and patients being offered allogeneic HPC transplantation. Published standards for transplant programs such as those by the Foundation for the Accreditation of Cellular Therapies require ABO typing of both patients and donors, but do not specifically require that blood group disparity be a selection criterion for proceeding to transplantation. 135 The Societe Francaise de Greffe de Moelle realized the existing heterogeneity of transfusion practices and recognized the importance of standard management techniques for patients enrolled into a clinical study comparing PBPC and marrow transplantation. 125 For this study, patients and donors underwent comprehensive phenotyping of red cell antigens including Rh, Kell and Lewis, and required transfusion support with red cells compatible to both donor and recipient beginning at day 0, and earlier if possible. Post-transplant identification and titration of isoagglutinins was also required. Donors with ABO isoagglutinin titers greater than 1:32 or antibodies to other red cell antigens present on recipient red cells were excluded from this study. A survey by Gruppo Italiano Trapianto di Midollo Osseo of 34 transplant centers identified a variety of pre-and post-transplant testing protocols and transfusion practices including some centers that allowed transfusion of recipient-type red cells after minor ABOincompatible transplants. 136 An appropriate quality management plan should address the possibility of red cell incompatibility in donor selection policies. The transplant program may elect to modify conditioning regimens, stem cell source, cell processing and post-transplant immunosuppressive regimens for recipients of red cell-disparate HPC products, based on the deleterious effects that may be otherwise experienced.
The quality management procedures must also have a failsafe mechanism whereby the blood bank is notified of allogeneic HPC recipients in order that appropriate transfusion practices can be established for the individual patient. In the minor ABO setting, typing of the patient will identify only patient red cells, and transfusion of red cells of host type may greatly exacerbate the severity of delayed hemolysis by passenger lymphocytes. In this setting, only by appropriate notification will the blood bank be aware of the need to supply blood products of appropriate type. Red cell components should be packed or washed to reduce plasma volume, or components from donors with low isoagglutinin titers. Shown are the first choice for platelet support; platelets from other blood groups can also be infused, but attention should be given to donor isoagglutinin titers.
